Cabbacis Innovative Approach to Harm Reduction for Smokers

In a world with over a billion smokers, the quest for harm reduction in tobacco usage is more urgent than ever. Enter Kabakis, a pioneering company at the forefront of this movement. Led by Joseph Pandolfino, Kabakis aims to address this colossal market with innovative products designed to drastically reduce nicotine consumption while satisfying smokers’ cravings.

Kabakis’ signature products, the iBLEND cigarettes and vaporizer pods, stand out in the market due to their unique composition. These products contain tobacco with 95% less nicotine compared to conventional cigarettes, combined with hemp that has less than 0.3% THC. This formulation not only aligns with emerging FDA regulations but also exploits Kabakis’ robust portfolio of 35 worldwide patents, providing a competitive edge.

Located in Niagara Falls, New York, Kabakis boasts a seasoned management team with over fifty years of collective experience in the tobacco industry. The company’s strategic vision is supported by a solid manufacturing setup and a proven track record in product development. Their expertise was highlighted in the creation of Spectrum research cigarettes for the National Institute of Drug Abuse, which contributed to the FDA’s proposed nicotine mandate.